Clinical Trial Update: More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents [Phase 1, Phase 2]

View source ↗

Summary

The MOCHA study reports Phase 1/2 results for HIV-infected children and adolescents treated with oral and long-acting injectable cabotegravir and rilpivirine; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• APRETUDE (CABOTEGRAVIR)
• Edurant (rilpivirine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-05-14